Treating oral mucositis with a supersaturated calcium phosphate rinse: comparison with control in patients undergoing allogeneic hematopoietic stem cell transplantation
- PMID: 22736463
- PMCID: PMC3411282
- DOI: 10.1007/s00520-012-1489-5
Treating oral mucositis with a supersaturated calcium phosphate rinse: comparison with control in patients undergoing allogeneic hematopoietic stem cell transplantation
Abstract
Purpose: Of patients undergoing allogeneic hematopoietic stem cell transplantation (HSCT), 75% or more experience oral mucositis, a painful acute complication that can delay discharge, interrupt treatment, and threaten life. To evaluate the efficacy of a supersaturated calcium phosphate rinse (SCPR), we compared it with customary care--topical mouth solutions--on measures of severity and consequent interventions and complications.
Methods: In this randomized controlled trial, 40 patients undergoing allogeneic HSCT were randomized: 20 to SCPR four times daily and 20 to solutions made with salvia leaf extract, iodine-povidine, and fluconazole. Treatment extended from initiation of conditioning treatment until the granulocyte count was ≥0.2 g/L. Mucositis severity was measured daily by a hematologist according to a World Health Organization (WHO) scale and self-assessed by patients. Need for interventions [analgesics, total parenteral nutrition (TPN), and granulocyte colony-stimulating factor] and complications (acute graft-versus-host disease and infections) were also assessed.
Results: In comparison with the control group, the SCPR group had significantly lower mean measures of WHO oral toxicity (0.9 vs. 1.8; P = 0.02), disease course (3.2 vs. 7.1 days; P = 0.02), and peak mouth pain (0.85 vs. 1.75; P = 0.005). Analgesic need was significantly shorter (1.1 vs. 3.4 days; P = 0.047) and the need for TPN significantly lower (0 vs. 6 patients; P = 0.02; 0 vs. 1.9 mean days; P = 0.009). Measures of complications were lower in the SCPR group, but not significantly so. Trial limitations include the impracticality of achieving double blinding with agents so different in appearance and in preadministration preparation.
Conclusions: Compared with the control group, the SCPR group had significantly lower mean measures of oral toxicity, peak mouth pain, and disease course duration. These results warrant confirmation in controlled, multicenter, randomized trials.
Figures
Similar articles
-
Supersaturated Calcium Phosphate Rinse in Prevention and Treatment of Mucositis in Patients Undergoing Hematopoietic Stem Cell Transplant.Exp Clin Transplant. 2017 Oct;15(5):567-570. doi: 10.6002/ect.2016.0180. Epub 2017 Feb 23. Exp Clin Transplant. 2017. PMID: 28229803
-
Mucositis after allogeneic hematopoietic stem cell transplantation: a cohort study of methotrexate- and non-methotrexate-containing graft-versus-host disease prophylaxis regimens.Biol Blood Marrow Transplant. 2005 May;11(5):383-8. doi: 10.1016/j.bbmt.2005.02.006. Biol Blood Marrow Transplant. 2005. PMID: 15846292
-
The effect of a supersaturated calcium phosphate mouth rinse on the development of oral mucositis in head and neck cancer patients treated with (chemo)radiation: a single-center, randomized, prospective study of a calcium phosphate mouth rinse + standard of care versus standard of care.Support Care Cancer. 2013 Oct;21(10):2663-70. doi: 10.1007/s00520-013-1829-0. Epub 2013 May 18. Support Care Cancer. 2013. PMID: 23686379 Clinical Trial.
-
Incidence, severity, and temporal development of oral complications in pediatric allogeneic hematopoietic stem cell transplant patients - a multicenter study.Support Care Cancer. 2023 Nov 16;31(12):702. doi: 10.1007/s00520-023-08151-1. Support Care Cancer. 2023. PMID: 37971651 Free PMC article. Review.
-
Efficacy of a supersaturated calcium phosphate oral rinse for the prevention and treatment of oral mucositis in patients receiving high-dose cancer therapy: a review of current data.Eur J Cancer Care (Engl). 2013 Sep;22(5):564-79. doi: 10.1111/ecc.12073. Epub 2013 Jun 4. Eur J Cancer Care (Engl). 2013. PMID: 23731197 Review.
Cited by
-
Oral mucositis caused by Candida glabrata biofilms: failure of the concomitant use of fluconazole and ascorbic acid.Ther Adv Infect Dis. 2017 Jan;4(1):10-17. doi: 10.1177/2049936116684477. Epub 2017 Feb 17. Ther Adv Infect Dis. 2017. PMID: 28357061 Free PMC article.
-
[Topical pain therapy in oral mucositis: a systematic review].Schmerz. 2013 Jun;27(3):253-62. doi: 10.1007/s00482-013-1318-x. Schmerz. 2013. PMID: 23685992 German.
-
Mineral derivatives in alleviating oral mucositis during cancer therapy: a systematic review.PeerJ. 2015 Feb 12;3:e765. doi: 10.7717/peerj.765. eCollection 2015. PeerJ. 2015. PMID: 25699212 Free PMC article.
-
Calcium orthophosphates in dentistry.J Mater Sci Mater Med. 2013 Jun;24(6):1335-63. doi: 10.1007/s10856-013-4898-1. Epub 2013 Mar 7. J Mater Sci Mater Med. 2013. PMID: 23468163 Review.
-
Adjunctive Treatments for the Prevention of Chemotherapy- and Radiotherapy-Induced Mucositis.Integr Cancer Ther. 2018 Dec;17(4):1027-1047. doi: 10.1177/1534735418794885. Epub 2018 Aug 23. Integr Cancer Ther. 2018. PMID: 30136590 Free PMC article.
References
-
- Wardley AM, Jayson GC, Swindell R, Morgenstern GR, Chang J, Bloor R, Fraser CJ, Scarffe JH. Prospective evaluation of oral mucositis in patients receiving myeloablative conditioning regimens and haemopoietic progenitor rescue. Br J Haematol. 2000;110:292–299. doi: 10.1046/j.1365-2141.2000.02202.x. - DOI - PubMed
-
- Sonis ST, Elting LS, Keefe D, Peterson DE, Schubert M, Hauer-Jensen M, Bekele BN, Raber-Durlacher J, Donnelly JP, Rubenstein EB. Perspectives on cancer therapy-induced mucosal injury: pathogenesis, measurement, epidemiology, and consequences for patients. Cancer. 2004;100:1995–2025. doi: 10.1002/cncr.20162. - DOI - PubMed
-
- Epstein JB, Schubert MM. Oropharyngeal mucositis in cancer therapy. Review of pathogenesis, diagnosis, and management. Oncology (Williston Park) 2003;17:1767–1779. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Research Materials